<I wouldn't have dumped a million bucks into progenetics. Think about the associated dilution relative to this last placement 1 million dollars amounts to. I wouldn't have bought back shares from genzyme a few years ago for ten million.>
I do agree with you. The progenetics deal should have been delayed until a US partnership for ATIII was in place. I also wasn't pleased with the GENZ. These are management failures or at least management disregard for current shareholders.